


CLAIMS

1. A method for treating severe heart failure, comprising administering to a patient in need thereof a therapeutically effective amount of a benzazepine compound
5 of the formula (1):



wherein R^1 is a hydrogen atom or a halogen atom, R^2 is a hydroxy group, or a group of the formula: $-NR^5R^6$ wherein R^5 and R^6 are the same or different and are each a hydrogen atom or a lower alkyl group, R^3 is a hydrogen atom, a
10 halogen atom, a lower alkyl group, or a lower alkoxy group, R^4 is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof.

2. The method for treating severe heart failure
15 according to claim 1, wherein the daily dose of the active compound is in the range of less than 0.6 mg/kg.

3. The method for treating severe heart failure according to claim 1, wherein the daily dose of the active compound is in the range from 0.1 mg/kg to less than 0.6

mg/kg.

4. The method for treating severe heart failure according to claim 1, wherein the dose of the active compound is in the range of 15 to 45 mg/body per day.


5 5. The method for treating severe heart failure according to claim 1, wherein the active compound is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

10 6. The method for treating severe heart failure according to claim 1, wherein the active compound is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)-benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

15 7. The method for treating severe heart failure according to any one of claim 1 to 6, wherein the severe heart failure is acute heart failure or a chronic heart failure in acute exacerbation.

20 8. The method for treating severe heart failure according to any one of claim 1 to 6, wherein the severe heart failure is a severe heart failure of New York Heart Association Class: III and IV.

25 9. A medicament for the treatment of severe heart failure which comprises as an active ingredient a benzazepine compound of the formula (1):




wherein R^1 is a hydrogen atom or a halogen atom, R^2 is a hydroxy group, or a group of the formula: $-NR^5R^6$ wherein R^5 and R^6 are the same or different and are each a hydrogen atom or a lower alkyl group, R^3 is a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, R^4 is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof.

10. The medicament according to claim 9, wherein the active compound (1) is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

11. The medicament according to claim 9, wherein the active compound (1) is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition suitable for the treatment of severe heart failure, which comprises as an

active ingredient a benzazepine compound of the formula (1):



wherein R^1 is a hydrogen atom or a halogen atom, R^2 is a hydroxy group, or a group of the formula: $-NR^5R^6$ wherein R^5 and R^6 are the same or different and are each a hydrogen atom or a lower alkyl group, R^3 is a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, R^4 is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof in admixture with a conventional pharmaceutically acceptable carrier or diluent.


13. The pharmaceutical composition according to claim 12, wherein the active compound (1) is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition according to claim 12, wherein the active compound (1) is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-

tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition according to any one of claims 12 to 14, wherein the active compound (1) or a pharmaceutically acceptable salt thereof is contained in an amount of 1 to 70 % by weight based on the weight of the composition.

16. A use of a benzazepine compound of the formula (1):



10 wherein R¹ is a hydrogen atom or a halogen atom, R² is a hydroxy group, or a group of the formula: -NR⁵R⁶ wherein R⁵ and R⁶ are the same or different and are each a hydrogen atom or a lower alkyl group, R³ is a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, 15 R⁴ is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof for manufacturing a medicament suitable for the treatment of severe heart failure.

17. The use of a benzazepine compound (1) or a pharmaceutically acceptable salt thereof according to claim 16, wherein the active compound (1) is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

18. The use of a benzazepine compound (1) or a pharmaceutically acceptable salt thereof according to claim 16, wherein the active compound (1) is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

19. The use of a benzazepine compound (1) or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 18, wherein the active compound (1) or a pharmaceutically acceptable salt thereof is contained in the medicament in a daily dosage unit of the range of less than 0.6 mg/kg.